InvestorsHub Logo
Followers 234
Posts 26887
Boards Moderated 0
Alias Born 01/12/2013

Re: rafunrafun post# 93435

Thursday, 09/29/2016 8:28:58 AM

Thursday, September 29, 2016 8:28:58 AM

Post# of 426330
Raf,
Looking at the redacted document, Amarin was the likely supplier. Why? Because prior to Oct 16th AZN was interested in acquiring Amarin, there's no reason for AZN to do the study....they already purchased Omthera.

Did AZN benefit from ANCHOR SPA rescission? Yes, big time.

If AZN was interested in devaluing Amarin would they root for: no clinical trial interim looks (yes), start patent litigation with Amarin (yes), not launch Epanova (?)...did Amarin's patents stand up to their test (yes).

What roll if any did AZN's Clinical trial director Hiatt play in the Ad Com? (Unclear...except this should have been divulged as a conflict of interest)

I didn't get to you.... your fog is lifting and your starting to see the truth... Next comes extreme anger towards AZN & FDA. I was there, it was just two years ago.

BB

If you're not good at being yourself, then maybe that's being yourself!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News